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Introduction
Acute graft-versus-host disease (aGVHD) is one 
of the major causes of morbidity and mortality 
in children undergoing allogeneic hematopoietic 
cell transplantation (allo-HCT). Despite advanced 
methods of its prevention by optimizing donor 
matching with high-resolution DNA typing of 
human leukocyte antigens (HLA) and by improved 
prophylaxis with pharmacological compounds, 
the incidence of severe aGVHD still occurs in 
approximately 15–50% of children following allo-HCT 
[1, 2]. aGVHD is considered to develop from donor 
T-cell activation and recipient tissue inflammation. 
The inflammatory process can initiate from the whole 
microorganisms or even parts of bacteria and fungi 
which may translocate via the damaged mucosal 
barrier of the host gastrointestinal (GI) tract due to 
increased permeability after conditioning [3]. Thus, 
patients undergoing allo-HCT have microbiota 
disruption, defined as loss of diversity and expansion 
of pathogenic bacteria [4], which might result in 
higher mortality [5]. Data on adult patients after allo-
HCT showed that gut colonization with multidrug-
resistant (MDR) bacteria was associated with 
a significantly decreased overall survival (OS) 
because of an increased treatment-related mortality 
[6]. The factors that were responsible for this outcome 
included an increased rate of bacterial infections as 
well as a higher incidence of aGVHD. Based on the 
previous reports, within Polish Society of Pediatric 
Oncology and Hematology, we decided to use oral 
GI decontamination to suppress the intestinal tract 
microorganisms [7].
The objective of this study was to analyze whether the 
use of GI decontamination during the peritransplant 
period influenced the prevention of aGVHD and had 
an impact on OS in children undergoing allo-HCT.
Methods
Design of the study
All patients who underwent allo-HCT between 2011 
and 2014 in pediatric transplant centers belonging to 
Polish Society of Pediatric Oncology and Hematology 
were analyzed retrospectively for the impact of oral 
gut decontamination on aGVHD and OS.
Transplant procedures
Transplants were conducted according to local 
procedures and treatment protocols. Toxicities were 
graded with the use of the toxicity criteria of the 
Common Terminology Criteria for Adverse Events. 
aGVHD and chronic GVHD were diagnosed and 
graded according to standard criteria [8, 9].
Colonization
Most of the patients were routinely screened for GI 
colonization of the following MDR bacteria: methicillin-
resistant Staphylococcus aureus (MRSA), vancomycin-
resistant enterococcus (VRE), extended spectrum 
β-lactamase (ESBL)-producing Enterobacteriaceae, 
and carbapenemase-producing Enterobacteriaceae. 
MDR bacteria were determined microbiologically 
according to the criteria by Magiorakos et al. [10].
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Prophylaxis of infections
All patients stayed in a transplant ward with protective environment 
from the beginning of conditioning until about 1 month after HCT 
[11, 12] and standard of care was applied including prophylaxis of 
infections and supportive therapy. Most children were nonselectively 
given antimicrobials for suppression of potentially pathogenic gut 
bacteria, except those with inability to swallow the drugs. Oral GI 
decontamination was performed with the use of various drugs including 
oral ciprofloxacin, metronidazole, colistin, gentamicin, rifaximin, or 
rarely other compounds. The decontamination was started with the 
beginning of conditioning and usually finished between neutrophil 
engraftment and hospital discharge after allo-HCT. For antifungal 
prophylaxis, up to 2014 fluconazole was usually administered, 
and later posaconazole or voriconazole was used. Acyclovir was 
applied for prophylaxis of herpes simplex/varicella-zoster (HSV/
VZV) infections until 1 year after HCT. Preemptive monitoring and 
treatment strategy were performed for cytomegalovirus (CMV) and 
Epstein–Barr virus (EBV) reactivation. Prevention of Pneumocystis 
jiroveci pneumonia (PcP/PjP) was done with cotrimoxazole after 
neutrophil recovery until the end of immunosuppressive therapy.
Bioethical issues
All parents provided informed consent for allo-HCT, data analysis, 
and publication. Collection of rectal swabs was a standard practice in 
all hospitalized transplant patients according to the local guidelines. 
This study was approved by the Local Bioethical Committee as a 
part of a project of analysis of infectious complications in patients 
undergoing oncological or transplant treatment.
Statistical analysis
The primary end point of this study was OS after allo-HCT. Deaths from 
any cause were considered events. Surviving patients were censored 
at the last follow-up examination or at the date of subsequent allo-
HCT. Occurrence of aGVHD was a secondary end point. Incidence 
of aGVHD was calculated using the cumulative incidence method. 
Survival estimates were calculated using the Kaplan–Meier method 
and compared by the log-rank test. The impact of the use of oral 
antibiotics used in gut decontamination on aGVHD was performed 
with a multivariate logistic regression analysis. All statistical analyses 
were performed using SPSS version 25.0 (SPSS Inc., Chicago, IL).
Results
Demographics
Total number of 459 children (176 girls and 283 boys) at median 
age 9.3 years (range: 0.1–18) after allo-HCT were included in this 
study. Children were treated for acute leukemia (n = 343), lymphoma 
(n = 19), MDS (n = 23), nonmalignant disorders (n = 47), and other 
diseases (n = 26), and 74.9% of patients were in complete remission. 
Myeloablative conditioning was applied in 73.8% of HCTs. The source 
of graft was peripheral blood in 52.9%, bone marrow in 44.7%, and 
cord blood in 2.4%. Graft was obtained from matched family donor 
in 25.7%, matched unrelated donor in 54.9%, mismatched unrelated 
donor in 22.6%, and haploidentical in 4.8%. GVHD prophylaxis 
was based on cyclosporin A in 92.6%, and rarely on tacrolimus or 
mycofenolate mofetil.
Decontamination
Decontamination with antibiotics was applied with 1–3 drugs 
(including combined or sequential administration) in 78% of 
children with oral ciprofloxacin (164 patients; 35.7%), metronidazole 
(86 patients; 18.8%), colistin (231 patients; 50.3%), gentamicin 
(92 patients; 20.0%), rifaximin (17 patients; 3.7%), or other 
compounds (15 patients; 3.2%).
Outcomes
The median time to neutrophil and platelet engraftment was 17 
(range: 9–60) and 19 (range: 0–516) days, respectively. Mucositis 
occurred in 90.4% of patients, aGVHD in 43.4% including aGVHD 
II–IV in 55% of them. GI aGVHD occurred in 16.7% and cGVHD in 
13.4% of 448 evaluable patients.
A 100-day and 1-year OS were 0.884 ± 0.015 and 0.787 ± 0.019, 
respectively. Decontamination had no impact on OS (p = 0.11), neither 
as a strategy nor for any individual drug. Also, decontamination had 
no impact on incidence of aGVHD (p = 0.3), however, it significantly 
decreased incidence of GI aGVHD (p = 0.030) (Fig. 1). No impact of 
decontamination on incidence of other organ involvement, including 
acute skin GVHD, was found.
Impact of antibiotics on GI aGVHD
In a multivariate logistic regression analysis, any aGVHD increased 
occurrence of GI aGVHD (p < 0.001), while decontamination had 
inhibiting effect on GI aGVHD (p = 0.037). In analysis of drugs used 
in decontamination, the following antibiotics significantly contributed 
to decreased GI aGVHD: ciprofloxacin (p < 0.05), metronidazole 
(p < 0.05), colistin (p < 0.05), and gentamicin (p < 0.05).
Discussion
This study was aimed to analyze the impact of gut decontamination 
on the development of aGVHD and OS in children after allo-HCT. 
Most of the patients transplanted in pediatric centers received 
oral decontamination with antibiotics. We have found that 
decontamination had no impact on OS and aGVHD incidence in 
this heterogeneous cohort of patients. However, we have shown 
that gut decontamination reduced the incidence of GI aGVHD. This 
observation supports gut decontamination before and after allo-HCT 
to reduce GVHD incidence and severity. Avoiding gut GVHD and 
mucositis might result in decrease of diarrhea episodes and lead to 
better tolerance of oral meals, less requirements for total parenteral 
nutrition, and improved overall quality of life.
It is already well-documented that the gut microbiome exerts 
immunomodulatory effect after allo-HCT [5, 13]. With respect to 
antibiotics, it has been shown previously that decontamination with 
the use of metronidazole before allo-HCT contributed to a decreased 
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incidence and severity of aGVHD [14]. However, recent studies linked 
the use of some antibiotic to the severity and incidence of GVHD: the 
use of piperacillin – tazobactam or imipenem – cilastatin has led to 
increased microbiota injury and resulted in increased GVHD severity 
[15]. Thus, altered gut microbiota, particularly absence or presence of 
specific bacteria, might be correlated with severity of GVHD and OS. 
Such findings supported the hypothesis of significant contribution of 
intestinal bacteria to aGVHD pathophysiology [15].
In our study, we have shown that apart from metronidazole, ciprofloxacin, 
colistin, and gentamicin might also reduce incidence of acute gut GVHD. 
Nevertheless, we did not analyze the impact of oral antibiotics on 
incidence of chronic GVHD, as in the case of chronic GVHD the influence 
of many immunological factors should also be taken into account. This 
manuscript presents results of preliminary analyses. Detailed analysis of 
impact of specific antibiotics is planned by our team.
Gut colonization in patients qualified to treatment with allo-
HCT probably results from the development of drug-resistance 
mechanisms during numerous lines of antibiotic treatment used in 
the treatment of infectious and febrile complications of intensive 
chemotherapy. This can lead to dissemination of infection including 
sepsis. Prevention of such complication should be regarded as a 
standard practice in these severely immunocompromised patients. 
Although association between intestinal microbiome and transplant 
outcomes has not been univocally proven, we have shown that oral 
gut decontamination decreases the incidence of acute gut GVHD.
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Fig. 1. Impact of decontamination on incidence of acute graft-versus-host disease: (A) 









Fig. 1. Impact of decontamination on incidence of acute graft-versus-host disease: (A) overall and (B) gastrointestinal
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